CO6251358A2 - Aspartato de acido -ciclopropil-6 - Google Patents

Aspartato de acido -ciclopropil-6

Info

Publication number
CO6251358A2
CO6251358A2 CO09120908A CO09120908A CO6251358A2 CO 6251358 A2 CO6251358 A2 CO 6251358A2 CO 09120908 A CO09120908 A CO 09120908A CO 09120908 A CO09120908 A CO 09120908A CO 6251358 A2 CO6251358 A2 CO 6251358A2
Authority
CO
Colombia
Prior art keywords
aspartic acid
acid
methoxyimino
naphthyridine
diaza
Prior art date
Application number
CO09120908A
Other languages
English (en)
Inventor
Jei Man Ryu
Dong Rack Choi
Jing Yang
Sue Hye Yoon
Seung Hwan Kim
Sae Kwang Ku
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Publication of CO6251358A2 publication Critical patent/CO6251358A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen sales de ácido aspártico de ácido 1-ciclopropil-6--fluoro-7-(8-metoxiimino-26-diaza-espiro [3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridina-3-carboxílico, métodos para preparar el mismo, y composiciones farmacéuticas antimicrobianas que comprenden el mismo. 1.- Una sal de ácido aspártico del ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridina-3-carboxílico representada por la Fórmula (I):2.- La sal de ácido aspártico del reivindicación 1, en donde el ácido aspártico se selecciona de ácido D-aspártico, ácido L-aspártico, ácido DL-aspártico o una mezcla no racémica de ácido D-aspártico y ácido L-aspártico. 3.- Un método para preparar la sal de ácido aspártico del ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4) oct-6-il)-4-oxo-1,4-dihidro-[1 ,8]naftiridina-3-carboxílico de la reivindicación 1, que comprende una etapa de hacer reaccionar ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridina-3-carboxílico con ácido aspártico en un disolvente. 4.- El método de la reivindicación 3, en donde el disolvente es por lo menos uno seleccionado del grupo que consiste de acetato de etilo, metanol, etanol, isopropanol, acetona, acetonitrilo, hexano, isopropil éter, y agua. 5.- El método de la reivindicación 3, en donde el ácido aspártico se selecciona de ácido D-aspártico, ácido L-aspártico, ácido DL-aspártico o una mezcla no racémica de ácido D-aspártico y ácido L-aspártico. 6.- Una composición farmacéutica antimicrobiana que comprende la sal de ácido aspártico del ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridina-3-carboxílico.
CO09120908A 2007-04-13 2009-10-27 Aspartato de acido -ciclopropil-6 CO6251358A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20070036574 2007-04-13

Publications (1)

Publication Number Publication Date
CO6251358A2 true CO6251358A2 (es) 2011-02-21

Family

ID=39864109

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09120908A CO6251358A2 (es) 2007-04-13 2009-10-27 Aspartato de acido -ciclopropil-6

Country Status (17)

Country Link
US (1) US8324238B2 (es)
EP (1) EP2134712B1 (es)
JP (1) JP5194105B2 (es)
KR (1) KR100953271B1 (es)
CN (1) CN101679416B (es)
AU (1) AU2008239966C1 (es)
BR (1) BRPI0810192C1 (es)
CA (1) CA2683939C (es)
CO (1) CO6251358A2 (es)
DK (1) DK2134712T3 (es)
EC (1) ECSP099736A (es)
ES (1) ES2436140T3 (es)
HK (1) HK1133881A1 (es)
MX (1) MX2009011063A (es)
PL (1) PL2134712T3 (es)
PT (1) PT2134712E (es)
WO (1) WO2008127060A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080109108A (ko) 2007-06-12 2008-12-17 (주)엘티엠에이피 휴대단말기용 스텝 힌지
KR101468659B1 (ko) 2009-07-27 2014-12-05 주식회사 아리바이오 Ｒ-7-(3-아미노메틸-4-메톡시이미노-3-메틸-피롤리딘-1-일)-1-시클로프로필-6-플루오로-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 ｌ-아스파르트산염, 이의 제조방법 및 이를 포함하는 항균용 약학적 조성물
KR101646324B1 (ko) * 2014-03-04 2016-08-05 동화약품주식회사 1-시클로프로필-6-플루오로-7-(8-메톡시이미노-2,6-디아자-스피로[3,4]옥트-6-일)-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 디-아스파르트산염의 수화물 및 이를 포함하는 항균활성 조성물
CN103922987B (zh) * 2014-05-04 2016-09-28 苏州天马精细化学品股份有限公司 一种扎布沙星中间体及其合成方法
KR102213991B1 (ko) * 2014-05-20 2021-02-09 동화약품주식회사 개선된 자보플록사신의 제조방법
CN114894924B (zh) * 2022-04-21 2024-06-21 徐州医科大学 一种通过非衍生化gc-ms同时测定人血浆中4种抗癫痫药物的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA824096B (en) * 1981-06-11 1983-04-27 Warner Lambert Co Salts of antimicrobial naphthyridine and quinoline compounds
ES8304117A1 (es) 1981-06-11 1983-02-16 Warner Lambert Co "un procedimiento para preparar sales de compuestos de naftiridina y quinoleina".
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
KR960000223A (ko) * 1994-06-08 1996-01-25 김정순 신규한 피리돈 카르복실산 화합물을 함유한 수용액 및 이의 제조방법
EP0994878B1 (en) * 1997-06-26 2001-11-28 Dong Wha Pharmaceutical Industrial Co. Ltd. Quinolone carboxylic acid derivatives
WO2001024803A2 (en) * 1999-10-04 2001-04-12 John Carter Pharmaceutical compositions containing copper, salicylic acid and vitamines c
SI1492789T1 (sl) * 2002-04-08 2006-10-31 Pfizer Derivati tropana kot modulatorji CCR5

Also Published As

Publication number Publication date
DK2134712T3 (da) 2013-11-18
ES2436140T3 (es) 2013-12-27
JP5194105B2 (ja) 2013-05-08
CA2683939C (en) 2012-06-19
WO2008127060A1 (en) 2008-10-23
KR100953271B1 (ko) 2010-04-16
PL2134712T3 (pl) 2014-01-31
BRPI0810192C1 (pt) 2021-05-25
HK1133881A1 (es) 2010-04-09
KR20080092893A (ko) 2008-10-16
BRPI0810192A2 (pt) 2014-12-30
AU2008239966B2 (en) 2011-11-10
CA2683939A1 (en) 2008-10-23
JP2010523649A (ja) 2010-07-15
AU2008239966C1 (en) 2012-03-29
MX2009011063A (es) 2009-10-30
EP2134712A1 (en) 2009-12-23
BRPI0810192B8 (pt) 2019-09-10
BRPI0810192B1 (pt) 2019-09-03
CN101679416A (zh) 2010-03-24
PT2134712E (pt) 2013-11-26
ECSP099736A (es) 2010-02-26
AU2008239966A1 (en) 2008-10-23
CN101679416B (zh) 2012-06-27
EP2134712A4 (en) 2011-07-27
US8324238B2 (en) 2012-12-04
US20100184795A1 (en) 2010-07-22
EP2134712B1 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
CO6251358A2 (es) Aspartato de acido -ciclopropil-6
NZ745595A (en) Biologically active cannabidiol analogs
WO2009095479A3 (en) Prodrug comprising a self-cleavable linker
EP3287449A3 (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
HK1138735A1 (en) Disinfectant
CA2557017A1 (en) Process for preparing n-protected 4-ketoproline derivatives
WO2014086499A8 (en) Neurotensin receptor ligands
EP1829863A4 (en) ARYLALCANOIC ACID DERIVATIVE
NZ594930A (en) Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
WO2011018635A3 (en) Photosensitizing compositions
WO2009156951A3 (en) 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
WO2009007137A3 (en) Pharmaceutical composition for topical application of poorly soluble compounds
SI1970372T1 (sl) Soli 9-oksoakridin-10-ocetne kisline z 1-alkilamino-1-deoksi-polioli
NO20080788L (no) Aripiprazolsalter
DE60023720D1 (de) Zusammensetzung für inhalierung enthaltend delta-9-tetrahydrocannabinol in einem semi-wässrigen lösungsmittel
Adamovich et al. Biologically active protic (2-hydroxyethyl) ammonium ionic liquids. Liquid aspirin
WO2012060590A3 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
UY28828A1 (es) Nueva forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s, 6s-2,8-diazabiciclo(4.3.0)nonan-8-il)-6-fluoro-1,4-dihidro-4-oxo-3-quinolincarboxílico
ES2208253T3 (es) Nuevo derivado de adamantano y composicion desinfectante acuosa que lo contiene.
WO2009021957A3 (en) Tricyclic heterocyclic compounds as gaba a modulators
GB0103046D0 (en) Organic Compounds
TW200734341A (en) Process for the preparation of sulfonic acid salts of oxabispidines
SG153774A1 (en) New 1h-indol-1-yl-urea compounds, a process for their preparation and pharmaceutical compositions containing them
TH97645B (th) ตัวกระทำที่เป็นพิษต่อเซลล์ซึ่งประกอบด้วยอนุพันธ์โทเมย์มัยซินใหม่ และการใช้ในทางอายุรเวทของมัน
AR125144A1 (es) Nuevo proceso

Legal Events

Date Code Title Description
FC Application refused